Company intelligence / Profile preview

PhycoWorks

London, England, United Kingdomphycoworks.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

PhycoWorks developed an AI-powered synthetic biology platform to engineer algae strains that convert CO₂ and waste into valuable chemicals and materials. The company's mission was to enable sustainable, circular bioeconomy solutions by replacing fossil-based manufacturing with renewable bioproduction. It targeted industries seeking greener alternatives for chemical production, leveraging advanced computational models to optimize strain performance and process efficiency. As of the latest filings, the company entered administration in the UK in early/mid–2024[7].

Industry: Non-Drug Biotech

Beyond the preview

Go deeper on PhycoWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhycoWorks.

Explore the full profile